Standout Papers

Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF... 2020 2026 2022 2024222
  1. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial (2020)
    Atul Deodhar, Philip Helliwell et al. The Lancet

Immediate Impact

1 by Nobel laureates 4 from Science/Nature 54 standout
Sub-graph 1 of 21

Citing Papers

Crohn's disease
2024 Standout
Systemic lupus erythematosus
2024 Standout
4 intermediate papers

Works of Bei Zhou being referenced

Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in Patients With Psoriatic Arthritis
2021
Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study
2018
and 1 more

Author Peers

Author Last Decade Papers Cites
Bei Zhou 741 694 416 67 1.8k
Jer-Yuarn Wu 487 628 646 43 2.4k
Su‐Jin Moon 714 549 719 82 1.9k
Keisuke Hagihara 348 517 552 55 1.9k
Mark P. Fletcher 671 406 463 42 1.8k
Pankaj Gupta 978 492 604 69 2.5k
Bin Zhou 615 656 756 87 2.1k
Dongyi He 827 542 792 41 2.2k
Jing Lu 605 370 517 80 1.5k
A. J. G. Swaak 420 638 462 65 2.4k
Helga Gleichmann 833 142 298 64 2.2k

All Works

Loading papers...

Rankless by CCL
2026